Keywords: AstraZeneca, Optimer, Fidaxomicin, Clostridium difficile, South America, Licensing
AstraZeneca inks deal for Optimer's fidaxomicin in Latin America
Article | 04 December 2012
USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish drug major AstraZeneca to commercialize fidaxomicin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
